|Description||Amrinone is a selective cAMP phosphodiesterase (PDE-3) inhibitor with positive inotropic and vasodilatory activity. It is a simple, non-glycoside cardiotonic agent. It provides protection against ischemia-reperfusion injury in kidney, liver, and heart. It has the ability to stimulate calcium ion influx into the cardiac cell. It is used in the treatment of congestive heart failure. It increases cardiac contractility as a vasodilator. It acts by inhibiting the breakdown of both cAMP and cGMP by the phosphodiesterase (PDE3) enzyme. It is a drug that may improve the prognosis in patients with congestive heart failure. It has been shown to increase the contractions initiated in the heart by high gain calcium induced calcium release (CICR). It was developed by Sanofi and has been listed.|
|Appearance||Pale Beige to Yellow Solid|
|Solubility||DMSO (Slightly), Methanol (Slightly)|
|Application||Amrinone is a simple, non-glycoside cardiotonic agent. It provides protection against ischemia-reperfusion injury in kidney, liver, and heart. It is used in the treatment of congestive heart failure. It increases cardiac contractility as a vasodilator.|
|Quality Standard||CP standard|
|Quantity||Kilograms to Tons|
|Boiling Point||451.5±45.0 °C | Condition: Press: 760 Torr|
|Melting Point||295 °C (decomp)|
|Density||1.277±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||Amrinone was developed by Sanofi and has been listed.|
PDE1-IN-2 is an inhibitor of PDE1 that has IC50 values of 6, 140 and 164 nM for PDE1C, PDE1B and PDE1A, respectvely.
PDE1-IN-1 is a potent PDE1 inhibitor and neuroprotective agent.
RVT-501, also referred to E6005, is a selective phosphodiesterase 4 (PDE4) inhibitor (IC50= 2.8 nM) with potential effect to treat atopic dermatitis.
Amrinone is a selective cAMP phosphodiesterase (PDE-3) inhibitor with positive inotropic and vasodilatory activity. It is a simple, non-glycoside cardiotonic ag...
Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective tr...
TAK-063 is a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. TAK-063 is currently being evaluated in clinical trials for t...
BRL 50481 is a potent, selective substrate-competitive inhibitor of phosphodiesterase (PDE) 7 (Ki = 180 nM).
This active molecular is a Type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor originated by Chiesi Farmaceutici with IC50 value of 0.026 ± 0.006 nM. CH...
An orally active selective type 5 cGMP phosphodiesterase inhibitor.
Vesnarinone, a quinolinone derivative, is a cardiotonic agent. It has pharmacodynamic effects include inhibition of phosphodiesterase III (PDE3) activity, incre...
Olprinone(Loprinone) is a selective phosphodiesterase 3 (PDE3) inhibitor.
FR-229934 is a Type 5 cyclic nucleotide phosphodiesterase inhibitor. In Feb 2008, preclinical for Erectile dysfunction in Japan was discontinued.
Deltarasin inhibits the interaction of RAS with PDEδ with KD of 41 nM. Inhibition of PDEδ-KRAS interaction by Deltarasin suppresses proliferation of human pancr...
Win-62005 competitively and selectively inhibits cyclic GMP-inhibitable low Km cyclic AMP phosphodiesterase (PDE III) from rat heart and canine aorta (Kis= 25 a...
(R)-(-)-Rolipram is a potent and cAMP-specific PDE4 inhibitor. It is 2.5-fold more potent than (+)-rolipram in inhibiting membrane-bound PDE 4.
Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis,...
Olprinone is a selective phosphodiesterase 3 (PDE3) inhibitor. Olprinone is used as cardiotonic agent with positive inotropic and vasodilating effects. Olprinon...
Mirodenafil dihydrochloride is a newly developed oral phosphodiesterase type 5 (PDE-5) inhibitor developed for the treatment of erectile dysfunction.
PF-8380 blocks inflammation-induced LPA synthesis. PF-8380 works both in vitro and in vivo through direct inhibition of autotaxin. In human whole blood PF-8380 ...
CI-1018 is a selective type 4 phosphodiesterase inhibitor associated with vasculitis. CI-1018 has been in development to suppress inflammation.